Last reviewed · How we verify
soluble ferric pyrophosphate
At a glance
| Generic name | soluble ferric pyrophosphate |
|---|---|
| Also known as | SFP |
| Sponsor | Rockwell Medical Technologies, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis (PHASE2)
- Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol (PHASE2)
- Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (PHASE2)
- Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2) (PHASE3)
- Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (PHASE3)
- Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis (PHASE3)
- Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients (NA)
- Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |